Gilead Sciences, Inc. (GILD)
After hours:
- Reuters
Gilead widens battle against alleged counterfeit HIV drug ring
A federal judge in New York has frozen the assets of dozens of people and entities accused of operating a massive nationwide scheme to distribute counterfeit bottles of Gilead Sciences Inc HIV drugs, including two alleged "kingpins." Gilead, which has been pursuing alleged counterfeiters in a civil lawsuit since last year, said in a court filing unsealed on Wednesday it had uncovered an operation that was "staggering in scope," responsible for sales of hundreds of millions of dollars of counterfeit bottles of its top sellers Descovy, Genvoya and Biktarvy, and other medicines. U.S. District Judge Ann Donnelly's latest asset freeze order, also unsealed on Wednesday, targets more than 50 defendants newly added to Gilead's lawsuit.
- ACCESSWIRE
Gilead Sciences: WHO Expands Recommendation for Veklury(R) (Remdesivir) to Patients With Severe Disease in Latest Update to COVID-19 Guideline
Gilead Sciences, Inc. (Nasdaq:GILD) today announced updates to the World Health Organization's (WHO) Therapeutics and COVID-19: living guideline, which now conditionally recommends Veklury® (remdesivir) for the treatment of patients with severe COVID-19 and continues to conditionally recommend Veklury in those with non-severe COVID-19 at the highest risk of hospitalization.
- Simply Wall St.
In the wake of Gilead Sciences, Inc.'s (NASDAQ:GILD) latest US$2.4b market cap drop, institutional owners may be forced to take severe actions
To get a sense of who is truly in control of Gilead Sciences, Inc. ( NASDAQ:GILD ), it is important to understand the...
